HIGHLIGHTS
- who: MDPI from the Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo have published the research: Development of TGFu03b2-IL-2/15 Switch Receptor for Use in Adoptive Cell Therapy Carole Beck Nicholas Paul Casey Irene Neda Nejati Adam Yixin, in the Journal: Biomedicines 2023, 11, 459. of /2023/
- what: The study showed acceptable safety and a PSA30 response in 4 of 10 patients . The aim of this study was to develop a construct conferring tumor-targeting T_cells with improved functionality in a TGFu03b2-rich environment.
- how: The results . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.